Zealand Pharma A/s

Other

Boehringer Ingelheim International Gmbh

Jakob Lind Tolborg

Ditte Riber

Dieter Wolfgang Hamprecht

Keld Fosgerau

Wolfgang Rist

Leo Thomas

Torben Østerlund

Trine Skovlund Ryge Neerup

Rasmus Just

Pia Nørregaard

Robert Augustin

Marianne Brorson

Kamilla Rolsted

Eddi Meier

Jens Rosengren Daugaard

Marie Skovgaard

Camilla Ærteberg Bæk

Lone Frost Larsen

Ulrika Martensson

Dorthe Lennert Christensen Almholt

Gita Kampen

Ulrika Mårtensson

Pia NØRREGARD

Camilla ÆRteberg BÆK

Torben Osterlund

Pia Norregard

Trine Skovlund Neerup

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Acylated glucagon analogues

Acylated glucagon analogue

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Glucagon analogues and methods of use

The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.

Peptide conjugates of GLP-1 receptor agonists and gastrin and their use

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Glucagon analogues

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.

GLP-1 receptor agonist peptide gastrin conjugates

Growing community of inventors

Herlev, Denmark

Jakob Lind Tolborg